

Evaluation report on compliance with HTA licensing standards

Report date: **21 January 2026**



BioGrad Biobank
HTA licensing number 22707

Licensed under the Human Tissue Act 2004

Licensed activities

BioGrad Biobank
L13 1HD

- Storage of relevant material which has come from a human body for use for a scheduled purpose

Evaluation summary

At the HTA's request, the establishment submitted a self-assessment for evaluation of compliance against the HTA's licensing standards.

Evaluated self-assessments are intended to be proportionate and risk-based. They are one of several tools that the HTA uses to maintain regulatory oversight. The regulatory framework places responsibility for compliance with those undertaking regulated activities. Designated Individuals are responsible for the accuracy of self-assessments.

As part of this process, the Designated Individual (DI) reported the establishment (HTA licensing number 22707) was substantially compliant with HTA's licensing standards. Based on the assurances provided, the HTA takes overall compliance to be satisfactory.

The HTA advises the DI to review the following areas against published HTA guidance to ensure they are meeting regulatory expectations and all statutory obligations.

HTA licensing standard GQ2(b)

Ensure audit reports include who is responsible for follow-up actions and the timeframes for completing these.

HTA licensing standard GQ3(b)

Ensure relevant documents cover induction and training requirements.

HTA licensing standards T1(c) and T1(d)

Ensure complete traceability records during transfer and transport, strengthening documentation of staff involvement and handovers.

HTA licensing standard T2(b)

Ensure disposal records for fresh sample derivatives consistently capture date, reason and method of disposal.

The HTA cannot provide any guarantees or endorsements of licensed establishments, or their activities, based on self-assessments.

The frequency and format of future assessments of compliance will be determined by the HTA according to evaluated risk.

Final report issued: 21 January 2026